Media headlines about Histogenics (NASDAQ:HSGX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Histogenics earned a news impact score of 0.23 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.1163738132597 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several brokerages have recently weighed in on HSGX. Zacks Investment Research raised Histogenics from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a report on Monday, September 18th. HC Wainwright set a $4.00 price target on Histogenics and gave the company a “buy” rating in a research note on Wednesday, December 27th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $4.00 price target on shares of Histogenics in a research note on Thursday, December 21st.
Shares of Histogenics (NASDAQ:HSGX) opened at $2.78 on Friday. Histogenics has a one year low of $1.45 and a one year high of $3.13. The company has a market capitalization of $70.29, a price-to-earnings ratio of -2.01 and a beta of 1.43.
Histogenics (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. equities research analysts predict that Histogenics will post -1.12 earnings per share for the current year.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.